PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT05419193
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 168 participants
- Sponsor
- Registry
-
NCT05419193
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05419193. Randomized; single masking; primary purpose treatment. Start 2023-02-21 (actual); primary completion 2024-12-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)
- Acronym
- PRO-CHASE
- Condition
- Stroke
- Condition
- Vascular Accident
- Condition
- Intracranial Hemorrhages
- Condition
- Intracerebral Hemorrhage
- Condition
- Hemorrhagic Stroke
- Condition
- Stroke, Acute
- Intervention (Drug)
- Propranolol Hydrochloride
- Intervention (Other)
- control group
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05419193- Content hash
17a7aecbfeea2bdaadab54fe9a3715a77cfeac3791e7311d53146aeee9b07453